Company profile
NOVO NORDISK A S
NYSE:NVOBiotechnology: Pharmaceutical Preparations
Drug pipeline (57)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ACTIVELLA | approved | — | 21 | approved |
| ALHEMO | approved | — | 9 | approved |
| AWIQLI | approved | — | 0 | — |
| AWIQLI FLEXTOUCH | approved | — | 28 | approved |
| ESPEROCT | approved | — | 0 | — |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (1039)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02501161 | phase3 | completed | 2016-01-31 | 2018-10-03 | Novo Nordisk A/S | A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus |
| NCT01713530 | phase3 | completed | 2013-02-21 | 2014-01-09 | Novo Nordisk A/S | A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin |
| NCT02906917 | phase3 | completed | 2016-09-20 | 2017-08-31 | Novo Nordisk A/S | A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification |
| NCT02443155 | phase2 | completed | 2015-11-10 | 2018-08-31 | Novo Nordisk A/S | A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function |
| NCT04575181 | phase1 | completed | 2020-10-21 | 2021-12-10 | Novo Nordisk A/S | A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine |
FDA applications (36)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 761326 | 2026-03-26 | BLA | NOVO NORDISK INC. | |||||
Loading… | ||||||||
| NDA 218316 | 2025-12-22 | NDA | NOVO NORDISK INC | |||||
Loading… | ||||||||
| BLA 761315 | 2024-12-20 | BLA | NOVO NORDISK INC. | |||||
Loading… | ||||||||
| NDA 215842 | 2023-09-29 | NDA | NOVO NORDISK INC | |||||
Loading… | ||||||||
| NDA 215256 | 2021-06-04 | NDA | NOVO NORDISK INC | |||||
Loading… | ||||||||